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Abstract
Recently the protein myozap, a 54-kD polypeptide which is not a member of any of the known cytoskeletal and junctional protein multi-
gene families, has been identified as a constituent of the plaques of the composite junctions in the intercalated disks connecting the car-
diomyocytes of mammalian hearts. Using a set of novel, highly sensitive and  specific antibodies we now report that myozap is also a
major constituent of the cytoplasmic plaques of the adherens junctions (AJs) connecting the endothelial cells of the mammalian blood
and lymph vascular systems, including the desmoplakin-containing complexus adhaerentes of the virgultar cells of lymph node sinus.
In light and electron microscopic immunolocalization experiments we show that myozap colocalizes with several proteins of desmoso-
mal plaques as well as with AJ-specific transmembrane molecules, including VE-cadherin. In biochemical analyses, rigorous immuno-
precipitation experiments have revealed N-cadherin, desmoplakin, desmoglein-2, plakophilin-2, plakoglobin and plectin as very stably
bound complex partners. We conclude that myozap is a general component of cell–cell junctions not only in the myocardium but also
in diverse endothelia of the blood and lymph vascular systems of adult mammals, suggesting that this protein not only serves a spe-
cific role in the heart but also a broader set of functions in the vessel systems. We also propose to use myozap as an endothelial cell
type marker in diagnoses.
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Introduction
The enormous progress in the elucidation of the ultrastructural
organization and molecular composition of the intercellular
 junctions over the past decades has primarily been based on
intense cell fractionation and analytical biochemical work which,
together with immunolocalization microscopy, resulted in the
classification of four major molecular biologically defined
 categories: gap junctions, tight junctions, desmosomes and
adherens junctions (AJs; [1]). In addition, a number of novel
hybrid forms of junctions have been described, including the
extensive composite junctions (areae compositae) connecting the
cardiomyocytes of the adult mammalian heart, which represent
amalgamated forms of both ensembles, the desmosomes and the
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AJs [1–7]. In particular, in the field of heart development and car-
diac function, the definition and molecular analysis of the com-
posite junctions was of great importance as it provided the basis
for the molecular explanations of the human mutations which
result in arrhythmogenic right ventricular cardiomyopathies, a
frequent cause of sudden death in previously healthy individuals
[1, 7–13]. Detailed immunolocalization studies have also led to
the discovery of a special cell–cell junction system, the ‘complex
junctions’ (complexus adhaerentes), in parts of the lymphatic
vascular system, notably the lymph node sinus [14–16].
Recently, a novel kind of protein called myozap, encoded within
the so-called ‘myozap/GRINL1A’ gene complex [17], was discov-
ered as a major constituent of the cardiac composite junctions
which fulfills important functions in the heart and perhaps also in
other parts of the cardiovascular system [18]. Using in situ
hybridization and immunoblots, Seeger et al. [18] could further
show that myozap also exists in vascular structures of early
embryonal development of the mouse as well as in lung and aorta
tissues of different mammalian species. To further explore and
extend these findings and to identify and localize myozap out of
the heart, we have generated highly sensitive and specific
 monoclonal and polyclonal antibodies, which have allowed to
identify myozap as a general component of the AJ structures of
both the myocardium as well as major components of the blood
and the lymph vessel systems.
Materials and methods
Cardiac and vascular tissues
Bovine and adult or foetal porcine tissues of freshly killed animals were
obtained from a local slaughterhouse (Mannheim, Germany) or from the
abattoir of the Institute for Veterinary Genetics (Friedrich-Loeffler-
Institut, Mariensee, Germany). Mouse and rat tissues from animals of
various ages were obtained as reported [3, 18, 19]. Protocols for rapid
freezing and aldehyde fixations of tissue samples were essentially as
reported [3, 4, 14–16, 18, 19]. Some cryopreserved or formaldehyde-
fixed, paraffin-embedded human tissue samples were kindly provided by
Dr. R. Moll (Institute for Pathology, Universities of Marburg and Giessen,
Germany) or were obtained from the tissue bank of the National Center
for Tumour Diseases (NCT, Heidelberg, Germany). All tissue samples
were obtained and processed in compliance with the regulations of the
Ethics Committees of the Universities of Heidelberg and Marburg (see
also Refs. [3, 7, 15, 16, 18, 19]).
For endothelial monolayer preparations freshly obtained bovine aortae
were used directly or kept on ice under rinsing with ice-cold PBS contain-
ing CaCl2 [20, 21]. The aortae were opened with scissors and prepared so
that relatively large areas of endothelium could be harvested by gently
scraping off with the edge of a rubber policeman, a glass object slide, or a
coverslip. These native endothelial monolayers were then directly spread
on another object slide as described [20, 21]. The harvested endothelial
cell layers were monitored by microscopy, and well-preserved preparations
were chosen for further processing, be it by SDS-PAGE or fixation for 2
min. in methanol, followed by 5 min. in acetone, or by fixation for electron
microscopy [15, 16].
Cell cultures
Neonatal rat cardiomyocytes were isolated and cultured for 5–6 days as
described [7, 13]. Permanently growing mouse adult cardiomyocyte-
derived cells of line HL-1 were kept in culture as described [22]. Human
microvascular endothelial cells from dermis (HMVEC-D) or lung 
(HMVEC-L) were purchased from Lonza (Cologne, Germany) and grown in
culture according to Lonza protocols. Human umbilical cord venous
endothelial cells (HUVECs), calf pulmonary endothelial cells [23], lung 
carcinoma A549 cells [24], SV-80 fibroblasts [25] and HaCat keratinocyte
cultures [26] all were grown as described [27].
Biochemistry
For preparations of cell lysates, monolayer cell cultures were rinsed twice
briefly with PBS and suspended in SDS-PAGE sample buffer containing
benzonase (1:1000; Merck, Darmstadt, Germany) using a rubber police-
man. Tissue lysates were prepared using the same sample buffer, and hun-
dreds of selected cryostat sections of specific tissue regions were collected.
After  vigorous homogenization, cell or tissue lysates were heated to and
kept at ca. 95C for 4–5 min., centrifuged at 15,000 g for 10 min. and sub-
jected to SDS-PAGE, followed by transfer to PVDF membranes
(ImmobilonP; Millipore, Bedford, USA). 2D-PAGE with isoelectric
 focusing was performed as described [28]. For immunoblot analyses,
horseradish peroxidase-conjugated secondary antibodies were applied in
combination with an enhanced chemiluminescence system (ECL; Fisher
Scientific, Schwerte, Germany).
To minimize protein degradation, fractionations of cell and tissue
lysates were done on ice and with additions of protease inhibitors
(Complete Mini Inhibitor Tabs; Roche Diagnostics, Mannheim, Germany).
Cells were washed twice in PBS, scraped off the cell culture dish surface
with a rubber policeman and disrupted with a Dounce homogenizer (B.
Braun Biotech, Melsungen, Germany). Cryopreserved tissue samples
were sectioned in a Leica CM3050S research cryostat (Leica, Wetzlar,
Germany), and 100–200 sections were usually sampled for homogeniza-
tion in a Dounce homogenizer. Tissue or cell lysates were centrifuged at
10,000 g for 10 min. and the pellets were treated with 1% Triton X100 in
PBS (‘low salt buffer’; ‘PBST’), followed by centrifugation and another
extraction of the pellets in 1% Triton X100, 0.5 M NaCl in PBS (‘high salt
buffer’; ‘PBSTS’). After a final centrifugation step, the residual pellets,
referred to as ‘cytoskeletal’ or ‘insoluble fraction’ (‘Ins. Fract.’), were sus-
pended by homogenization in sample buffer. The proteins of the super-
natants of both types of extractions and of the residual pellets (‘insoluble
fraction’) were resuspended in sample buffer and precipitated in methanol
(1:4) at –20C overnight. Methanol was decanted and precipitates were
air-dried for few minutes, followed by resuspension in the same volume
of sample buffer (50–100 l), depending of the specific amount of cell or
tissue material.
For immunoprecipitation, freshly harvested HL-1 cells were washed
in PBS and scraped off the culture dish in the low salt buffer PBST
mentioned afore or in ‘RIPA buffer’ (150 mM NaCl, 5 mM EDTA, 20 mM
HEPES, pH 7.5, 1% Nonidet-P40, 0.2% deoxycholate, 0.1% SDS) as
described [29], followed by a brief but intense Dounce homogenizer
treatment. Lysates were centrifuged for 10 min. at 15,000 g, and the
supernatants were used for immunoprecipitation with antibodies coupled
to Dynabeads (Dynal, Hamburg, Germany) according to the supplier’s
protocol [30].
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Identification of the immunoprecipitation bands by electron spray ion-
ization (ESI) was performed in the Protein Analysis Core Facility (Dr. M.
Schnˆlzer) of the German Cancer Research Center.
Generation of antibodies
The full length clone of the protein encoded by the human myozap/GRINL1A
complex locus (accession no. ADA68358; cf. [17, 18]) in pCR4-TOPO vec-
tor was purchased from ImaGenes GmbH (Berlin, Germany). Polymerase
chain reaction was performed to add 5EcoRI/BglII(BamHI) and
3’SalI/EcoRI restriction sites for integration of the myozap/GRINL1A
sequence into the pQE30 protein synthesis vector. Myozap protein was pro-
duced in competent M15 pREP4 bacteria and purified using the QIAexpress
protein purification system (Qiagen, Hilden, Germany). Recombinant
myozap protein was then used to generate monoclonal antibodies (mAb
myozap clone 517.67 and mAb myozap clone 101.2) in BALB/c mice, using
the Monoclonal Antibody Core Facility (Dr. H. Zentgraf) of the German
Cancer Research Center. For the screening of the immunoglobulins secreted
by the specific clones, cryostat sections obtained with a Leica CM 3050S
cryostat (Leica) from mammalian heart tissue were mounted on 10-well
(6.7 mm) diagnostic object slides (Menzel, Braunschweig, Germany). For
antibody characterizations SDS-PAGE was performed with lysates contain-
ing the recombinant human myozap protein, using lysates of HL-1 cells or
of bovine heart muscle tissue. The mAb-containing hybridoma supernatants
were examined by immunoblotting using a 28-channel slot blot apparatus
(Biometra, Goettingen, Germany).
For direct immunizations, the following polypeptides were synthe-
sized (Peptide Specialty Laboratories, Heidelberg, Germany), represent-
ing the aminoterminal (hNT) and the carboxyterminal (hCT) amino acid
sequences of the human myozap protein, and conjugated to keyhole
limpet cyanin to trigger and enhance the immunoreaction. The polypep-
tides were mixed with Freud’s adjuvants (Sigma, St. Louis, MO, USA) and
used for the immunization of guinea pigs to generate polyclonal antibod-
ies to the following two epitope-bearing polypeptides: ‘Myozap GP1A/B
(hNT)’: MLRSTSTVTLLSGGAART(C); ‘Myozap GP2A/B (hCT)’: (C)
YTRVLELTMKKTLT.
Other antibodies
Antibodies used for comparisons have been described [29–31]. In addi-
tion, rabbit antisera against VE-cadherin (Cayman Chemical, Ann Arbor,
MI, USA) have been used.
Light and electron microscopy
Single- and double-label immunofluorescence microscopy was performed
as described elsewhere [3, 7, 15, 19, 29, 30]. For paraffin-embedded tis-
sue sections the antigen retrieval technique was applied for immunofluo-
rescence microscopy, usually for 10 min. at 120C in a Milestone
Microwave Vacuum Histoprocessor (Mikron, Vista, CA, USA) and in 0.1M
Tris-buffered saline containing 5% urea (pH 9.5). Images were obtained
with a Zeiss confocal laser scanning microscope (LSM 700; Zeiss, Jena,
Germany). 4,6-Diamidino-2-phenylindol (DAPI; Serva, Heidelberg) was
applied for staining nuclei [7], and standard transmission electron
microscopy as well as immunoelectron microscopy was performed as
repeatedly described [3, 7, 18, 19].
Results
Highly sensitive and specific myozap antibodies
The recent discovery of the protein myozap as a novel major
 constituent of the composite junctions of intercalated disks of the
mammalian heart [18] is especially remarkable as this cell mole-
cule represents a protein type in its own right that does not
belong to any of the multigene families known. This uniqueness
as well as some indications in Northern and Western blots that
myozap might also occur in specific cell types of certain other tis-
sues have prompted us to generate highly sensitive and specific
monoclonal as well as conventional antibodies that would allow
(i) the detection and localization of this protein, even in cells or
cell structures containing only very low amounts, (ii) the explo-
ration of myozap for diagnostic problems and (iii) further elucida-
tions of myozap functions. The four types of antibodies obtained
all meet these expectations. In the following, however, we pres-
ent, for the most part, results obtained with murine monoclonal
antibodies of clone 517.67.
Immunodetection of myozap and myozap-
 complexes in biochemical and immunolocalization
experiments using myocardiac cells
Using Northern and Western blot tests, protein myozap (Mr 54 kD)
had been detected not only in heart but also in placenta and lung
tissue [18]. Immunoblot analyses using the novel very sensitive
antibodies have now allowed us to identify this protein not only in
myocardial tissues of the diverse mammals examined but also in
cultures of murine cardiomyocyte-derived, permanently growing
HL-1 cells [22] as well as in lung tissue and, in lesser amounts, in
certain other tissues such as kidney and liver (Fig. 1, upper panel).
Fractionation experiments have further shown that protein myozap
is enriched in the Triton-insoluble, cytoskeletal residue fractions
containing cell–cell junction structures (Fig. 1, lower panel).
Remarkably, in these fractions relatively more  protein myozap has
been recovered than some of the ‘classic’ cell junction con-
stituents such as N-cadherin and plakoglobin (Fig. 1, lower panel).
Two-dimensional gel electrophoresis of the polypeptides present
in HL-1 cell lysates, followed by immunoblotting with the new
myozap antibodies, further allowed us to distinguish two major
variants of this polypeptide with isoelectric points of ca. 6.02 and
6.20. The novel murine monoclonal and guinea pig polyclonal
 antibodies also specifically and intensely decorated composite
junction structures, whether they occurred in frozen myocardial
tissue, in primary cultures of neonatal rat cardiomyocytes, or in
HL-1 cardiomyocyte cultures (Fig. 2A–C). In all comparative local-
ization experiments using myocardial tissue or HL-1 transformed
cardiomyocyte cultures (Fig. 2C–F) protein myozap showed partial
colocalization with several other junction plaque proteins, includ-
ing actin filament-binding ones (for an example, see protein ZO-1;
1712 © 2011 The Authors
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also recovered in the ‘low salt’ (PBS  1% Triton X100; ‘PBST’), the ‘high salt’ (PBS  1% Triton X100  0.5 M NaCl; ‘PBSTS’) and the residual
‘cytoskeletal’ fractions (insoluble fraction; ‘Ins. Fract.’), while myozap is highly enriched in the cytoskeletal fraction.
Fig. 2. Immunofluorescence microscopy of
protein myozap in the composite junctions
of mammalian cardiomyocytes. (A)
Immunofluorescence micrograph of a cryo-
stat section through bovine myocardium
using myozap mAb (clone 517.67, red), in
combination with nuclear DAPI staining
(blue) and phase contrast microscopy. 
Note the intense positive reaction of the
intercalated disks (IDS). (B) Double-label
immunofluorescence microscopy of pri-
mary cardiomyocyte cultures of neonatal
rat hearts, using murine mAbs to -cardiac
actin (green) and polyclonal guinea pig
antibodies to myozap (red), in comparison
with DAPI staining (blue). Note the specific
reaction of the composite junctions of the
IDS. (C–F) Cardiomyocyte-derived HL-1
mouse cells grown in dense culture mono-
layers and labelled with myozap mAb (red),
in a differential interference contrast (DIC)
image (C) or in comparison with the actin
microfilament-associated junctional protein
ZO-1 (D and E; green) and the major
adherens junction plaque protein -catenin
(F; green). Note the intense, specific reac-
tion of the composite junctions of the inter-
calated disk-derived structures (A, B). Note
also the colocalization of myozap with parts
of the structures positive for further
adherens junction-associated plaque pro-
teins (yellow merged colour in D–F). Bars:
100 m (A–C); 20 m (D–F).
Fig. 1. Immunoblot identification of protein
myozap after SDS-PAGE of the polypep-
tides of diverse cell culture lines and tis-
sues as well as cell fractions. Upper panel:
Myozap (~54 kD) detected in cell culture
lysates (mouse HL-1 cardiomyocytes,
human A549 lung epithelial cells, human
SV80 fibroblasts) and in lysates of various
mouse tissues (heart, lung, kidney, liver,
intestine, epidermis, brain), using a myozap
mAb (clone 517.67). Note that HL-1 cells
as well as heart and lung tissue contain
appreciable amounts of protein myozap,
whereas much lesser amounts are detected
in kidney and liver lysates and no signifi-
cant signal has been obtained in intestine,
epidermis and brain lysates. Lower panel:
Immunoblot demonstrations of myozap in
specific cell fractions of mouse HL-1 car-
diomyocyte lysates. Note that appreciable
amounts of N-cadherin and plakoglobin are
J. Cell. Mol. Med. Vol 16, No 8, 2012
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Fig. 2D and E) and members of the armadillo protein family 
(Fig. 2F presents -catenin for example).
When immunoprecipitation experiments using these myozap
antibodies were performed with extracts from cardiac tissue
 samples or from HL-1 cell cultures, followed by SDS-PAGE with
subsequent silver staining and immunoblotting, enrichments of
certain other polypeptides were noted (Fig. 3A). After the very
 rigorous extraction conditions in detergent-rich RIPA buffer, four
proteins consistently co-immunoprecipitated with myozap, which
were not found in controls, i.e. pellets from lysates incubated with
anti-species immunglobulin-coupled beads alone. When these
polypeptide bands were extracted and used for ESI mass spec-
tometry (Fig. 3A and B) they were identified as desmoplakin and
plectin (Fig. 3B).
Detailed immunoblot analyses of immunoprecipitation
experiments using HL-1 cell lysates revealed special molecular
binding of myozap to the cadherins, desmoglein Dsg-2 
(Fig. 3C, lane IP-D), and N-cadherin (Fig. 3C, lane IP-N),
whereas E-cadherin served as a negative control (Fig. 3C, lane
IP-E). In addition,  protein myozap was also demonstrated in
complexes with the plaque proteins plakophilin-2 (Fig. 3D) and
desmoplakin (Fig. 3E) and, in lesser amounts and less regularly,
-catenin (not shown). Vice versa, when more diluted HL-1 cell
lysates in RIPA or Triton-X100-containing buffer were used for
immunoprecipitations with myozap antibodies the pelleted
myozap complexes (Fig. 2Fa) were not demonstrably com-
plexed with protein ZO-1 (Fig. 3Fa, lane IP-Z). However, under
the same conditions myozap was found to be associated with
plakophilin-2 in nearly equimolar amounts with protein ZO-1
(Fig. 3Fb). Finally, under our experimental conditions protein
myozap was not detected in the protein ZO-1 immunoprecipi-
tates (Fig. 3Fc, d).
Fig. 3. Results of immunoprecipita-
tion experiments using myozap mAb
(clone 517.67) and mouse cardiomy-
ocyte HL-1 cell lysates. (A) SDS-PAGE
of polypeptides of fractions obtained
in immunoprecipitation experiments
as seen after silver staining: lane M:
broad range Mr reference molecules;
lane 1: initial RIPA buffer lysate; lane
2: supernatant of the ‘preclearing
step’; lane 3: supernatant after
myozap immunoprecipitation; lane
‘Pre’: polypeptides of the ‘preclearing
step’ absorbed to dynabeads; lane ‘IP’:
lysate of myozap immunoprecipitate.
Bands 1–4 denoted by arrows have
been used for electron spray ioniza-
tion (ESI) mass spectometry. Band 4,
arrow denotes the band containing
both myozap as well as residual
desmin and IgG heavy chain.
Arrowhead, immunoglobulin (IgM
heavy chain residual contamination).
(B) Table of results of ESI mass spec-
tometry of the extracted bands 1–4
(see arrows in A). Note that, together
with myozap (band 4), three other
proteins are detected in the immuno-
precipitates: desmoplakin (in band 3),
plectin (in bands 1 and 2) and the
intermediate filament protein desmin (in band 4). (C) Immunoblot reactions with myozap mAb: lane ‘RIPA’: initial RIPA buffer lysate; lane ‘Sup-E’: super-
natant of immunoprecipitation using E-cadherin antibodies; lane ‘Sup-N’: supernatant of N-cadherin immunoprecipitation; lane ‘Sup-D’: supernatant of
desmoglein-2 (Dsg-2) immunoprecipitation; lane ‘Sup-M’: supernatant of myozap immunoprecipitation; lane ‘Marker’: broad range protein Mr markers
(New England Biolabs, Frankfurt, Germany); Mr values are indicated on the left margin; lane ‘IP-M’: myozap immunoprecipitate; lane ‘IP-D’: desmoglein-
2 immunoprecipitate; lane ‘IP-N’: N-cadherin immunoprecipitate; lane ‘IP-E’: E-cadherin immunoprecipitate (negative control). (D, E) Fractions as in B,
showing immunoblot reactions with antibodies to plakophilin-2 (D) and desmoplakin (E). Lane designations as in C. Note that under these conditions
immunocomplexes of myozap with desmoplakin and plakophilin-2 are identified. (F) Specific parallel immunoprecipitations using antibodies to protein
myozap (IP-M; F, a), protein ZO-1 (IP-Z; F, a), VE-cadherin (IP-V; F, a), in comparison with the ‘pre-clearing’ pellet (‘Pre’; see also above) as negative
control. For comparison, immunoprecipitates obtained with antibodies to plakophilin-2 (b) and to protein ZO-1 using RIPA buffer (c) or Triton-X100-
containing buffer (d) are shown. The specific immunoblot reactions with antibodies to myozap (a), plakophilin-2 (b) and protein ZO-1 (c, d) are shown.
1714 © 2011 The Authors
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Identification of protein myozap in adhering 
junctions connecting blood vessel 
endothelial cells
Using the novel antibodies to myozap in immunofluorescence
microscopy we noted extensive reactions specific for endothelial
cells of blood vessels of a wide range of calibres and in all kinds
of tissues examined, from the zonulae adhaerentes of veins of dif-
ferent calibres to arteries and arterioles and even the smallest cap-
illaries (Fig. 4A and B). The endothelia of small foetal capillaries,
including those of human placenta, were also myozap-positive
(Fig. 4C and D), thus explaining the Northern blot results of Seeger
et al. [18]. In all types of blood vessels examined, the myozap anti-
bodies showed colocalization with -catenin (e.g. Fig. 4D) and all
the other endothelial armadillo proteins. By contrast, the AJs of
the one-layered placental epithelium were positive for E-cadherin
but negative for myozap whereas -catenin was also seen in colo-
calization with myozap (Fig. 4C and D).
Myozap also appeared to be remarkably enriched in the
endothelium of the alveolar part of the lung (Fig. 5A–E’’) but was
absent from the desmoplakin-positive, single-layered bronchial
epithelium (Fig. 5A–C). In contrast, plakoglobin consistently
showed co-localization with protein myozap in the endothelial cells
but not in the alveolar epithelia (Fig. 5D–D’’). The endothelial local-
ization was also demonstrable by the co-localization of myozap
with VE-cadherin (Fig. 5E’’).
Finally, in relatively large endothelial detachment (‘scraping
off’) preparations from bovine aortae, myozap also showed exten-
sive decoration of cell–cell boundaries, in partial colocalization
with VE-cadherin (Fig. 6A, A’) as well as with -catenin and the
armadillo proteins -catenin, protein p120 and plakoglobin (not
shown).
Thus, not unexpectedly we also found protein myozap in par-
tial association with -catenin (Fig. 6B) and VE-cadherin (Fig. 6C)
of the junctions connecting cultured endothelial cells of the
HUVEC type, in immunofluorescence labelling (Fig. 6B and C) as
well as in the pellet fractions of cell protein lysates in detergent-
containing buffers (Fig. 6D and E). These experiments showed
again the markedly low solubility of protein myozap, most of
which was recovered in the pelletable residues, i.e. dissociated
from the major endothelial junction glycoprotein, VE-cadherin
(compare Fig. 6D and E).
As in some tissues the epithelial and the microvascular struc-
tures in lung alveoli are very thin and very closely associated with
each other we also applied electron microscopy (Fig. 7A presents,
for example, a cross-section through such an association of a cap-
illary and an alveolar epithelial structure). Immunoelectron
microscopy then clearly showed that in such tissues protein
myozap was exclusively located in the plaques of the AJs of the
vascular endothelial cells (Fig. 7B and C) where it often could even
be resolved as specific for the cytoplasmic plaque structures and
absent from the membrane-to-membrane contact and interspace
region (Fig. 7D).
Fig.  4. Immunolocalization of protein
myozap in adherens junctions connecting
endothelial cells of blood vessels in cryo-
stat sections through bovine tongue (A, B)
and human placenta (C, D). (A) The
endothelial AJs of blood vessels of different
calibres are specifically and intensely posi-
tive for myozap. (B) Higher magnification of
the region in the square marked in (A). Note
the specific myozap immunostaining of AJs
in capillaries as well as in an arteriole. L:
lumen. (C) Cryostat section through human
placenta reacted with antibodies to myozap
(green) and E-cadherin (red). The AJs of
the microvasculature are strongly positive
for myozap, whereas the epithelial junc-
tions are negative for myozap but positive
for E-cadherin. (D) Merged image showing
the colocalization (yellow) of protein
myozap (red) and -catenin (green) in
microvascular endothelial AJs whereas
only -catenin is positive in the AJs of the
placental epithelium. Bars: 200 m (A), 50
m (B), 100 m (C, D).
J. Cell. Mol. Med. Vol 16, No 8, 2012
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Identification of protein myozap in the various
kinds of junctions connecting endothelial and
special endothelium-derived cells 
of the lymphatic system
In all four mammalian species examined, we have also identified
protein myozap as a major component of the AJs connecting the
endothelial cells of the lymphatic system, including the three-
dimensionally organized, multiramified cells of the virgultar
endothelium system of the lymph node sinus and various other
lymph vessel endothelia the cells of which are known to be con-
nected by a special kind of desmoplakin-containing junction, the
complexus adhaerens [14–16, 33–37]. The double-label
immunolocalizations of Fig. 8A–A’’ and B–B’’ clearly show that the
vast majority of the myozap label coincides with desmoplakin in
the lymph node sinus cells but is totally absent from the adjacent
desmosomes of the lymph node follicles (F in Fig. 8A–A’’). In addi-
tion, however, in higher resolution cross-sections through such
sinus (Fig. 8B–B’’) short intercepts positive for desmoplakin only
Fig. 5. Immunofluorescence microscopy of protein myozap in vascular endothelial AJs of lung alveolar tissue of various species and after different modes
of fixation. (A) Formaldehyde-fixed, paraffin-embedded adult porcine lung as seen after antigen retrieval and immunoreaction with myozap mAb 517.67
(red), in combination with nuclear DAPI staining (blue). (B) Myozap immunoreaction (green) on cryostat sections of adult mouse alveolar tissue. 
(C) Immunofluorescence labelling of the desmosomes in rat lung epithelium (desmoplakin, red), in comparison with myozap immunostaining (green) of
the alveolar capillaries. (D, D’, D’’) Double label immunofluorescence microscopy of plakoglobin (red in D) and myozap (green in D’) in alveolar regions,
seen on cryostat sections through mouse lung. (D’’) Merged image of (D) and (D’). Note colocalization of myozap with plakoglobin in microvascular
endothelial cells (yellow merge-colour in D’’), plakoglobin immunostaining only in the AJs connecting alveolar epithelial cells (red labelling pattern in D’’).
(E, E’, E’’) Double-label immunofluorescence microscopy of AJs of blood capillaries positive for VE-cadherin (red in E) as well as for myozap (green 
in E’). Note the almost complete colocalization of VE-cadherin and myozap (yellow merge colour) in the AJs of the endothelium (E’’). Bars: 100 m (A),
50 m (B–E’’).
1716 © 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 6. Bovine aortic endothelium in a fresh
detached cell layer preparation showing the
reaction of protein myozap in the zonulae
adhaerentes of a bovine aorta. (A)
Immunolocalization of myozap (red) in the
detached endothelium. (A’) Same region as
in (A) but in an optical channel showing
both VE-cadherin (green) and myozap (red)
reactions with far-reaching colocalization
(yellow merge colour). (B, C) Laser-scan-
ning double-label immunofluorescence
microscopy of cultured human endothelial
HUVEC cells, showing the partial associa-
tion of myozap (red) with other adherens
junction proteins such as (both in green) -
catenin (B) or VE-cadherin (C). (D, E)
Results of fractionation experiments of
HUVEC cell lysate proteins after SDS-PAGE
of polypeptides and immunoblotting with
antibodies to VE-cadherin (D) and myozap
(E) are shown. Presented are proteins of
the supernatants (lanes 1 and 3) and the
remaining pellet fractions (lanes 2 and 4)
after lysis using Triton-X100 (lanes 1 and 2)
or RIPA (lanes 3 and 4) buffer, showing the
relative recoveries of VE-cadherin (D) in
comparison with protein myozap (E) which
is predominantly detectable in the pellet
fractions of the detergent-containing pro-
tein lysates (arrowheads). The masses of
the molecular size markers (kD) are pre-
sented on the left margin of D. Bars: 100
m (A, A’); 20 m (B, C).
Fig. 7. (A) Transmission electron micro-
graphs of sections through mouse lung
alveoli. Note the close neighbourhood of
capillary endothelial (left part) and respira-
tory alveolar epithelial structures (right
part) structures (erythrocytes appear as
dark cells in the lumen of microcapillaries).
(B–D) Single-label immunoelectron
microscopy showing the specific ultra-
structural localization of protein myozap in
the zonulae adhaerentes connecting
endothelial cells. Note that the cytoplasmic
plaques of the endothelial AJ system are
entirely and strongly decorated by myozap-
antibodies coupled to colloidal gold parti-
cles (with silver enhancement), whereas
such labelling is absent from the mem-
brane contact region and the intercellular
connection structures (D). Bars: 5 m (A),
1 m (B), 0.5 m (C and D).
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could also be identified (see specifically Fig. 8B’’), a minor differ-
ence explained by the exceptionally extended desmopakin-positive
plaques characteristic of some complexus adhaerens junctions
[14–16, 32–35].
Discussion
Our results show that the junctional plaque protein myozap, which
shares some molecular organizational similarities but no true
sequence homology with ERM (ezrin, radixin, moesin) proteins, is
not specific to the composite junctions (areae compositae) of the
intercalated disks connecting the cardiomyocates but also occurs
in the AJs connecting the endothelial cells of most, probably all
blood and lymph vessels. This conclusion has been made possi-
ble by the high sensitivity of a series of novel mono- and poly-
clonal antibodies specific for this polypeptide. With these antibod-
ies we have also detected this architectonically important protein
in embryogenesis, in which so far only its mRNA had been shown,
as well as in parts of the vasculature of both the arterial and the
venous system. Using the novel antibodies our results now allow
the general conclusion that myozap occurs in almost all tissues,
namely as a general and major endothelial junction component of
the vascular elements present. This broader expression also
explains the previous observations that myozap also occurs as a
structural protein in non-cardiac organs such as placenta and
adult lung (this study and [18]).
Fig. 8. Double label immunofluorescence
microscopy of protein myozap in junctions
connecting the endothelial cells of the lym-
phatic vessel system, here on cryostat sec-
tions through bovine (A) and human (B)
lymph nodes. Note that the complexus
adhaerens junctions connecting the
endothelial cells of the virgultar arrange-
ments in the lymph node sinus regions are
positive for myozap (red in A and B) and
desmoplakin (green in A’ and B’) resulting
in yellow merge labelling (A’’ and B’’). In
contrast, the desmosomes of the follicular
dendritic reticulum (F) are strongly positive
for desmoplakin only (green in A’ and A’’).
Bars: 100 m.
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The high stability of myozap and its high resistance to extrac-
tions as demonstrated in the present report, together with its spe-
cific and tight binding to other adhering junction plaque molecules
such as desmoplakin, plakoglobin and plakophilin-2, indicate that
this molecule is deeply rooted and stably integrated in the plaque
structure. Interestingly, the myozap-binding desmosomal ‘marker’
proteins desmoplakin and plakophilin-2, which are known to be
absent in most forms of endothelial junctions of the adult blood
and lymph vessel system, have been found in the junctions of cer-
tain specific endothelial vessels and cell cultures as well as in
embryonal angiogenesis [14–16, 32–39]. On the other hand,
myozap is also a major plaque component in zonulae adhaerentes
of the great majority of blood and lymph vessels in which these
desmosomal type proteins are absent. Clearly, it will be a focus of
future experimental work to identify the complex partners of
myozap in the majority of endothelia, which are known to be
devoid of desmoplakin and plakophilin-2. In yeast-2-hybrid
screening experiments Seeger et al. [18] had noted myozap bind-
ing to protein ZO-1, and in specific transfection experiments using
human embryonal kidney cell cultures (line HEK293T) these authors
identified coimmunoprecipitation complexes of tagged constructs
of protein ZO-1 with tagged myozap constructs. Therefore, it was
to some surprise that we had to realize that in our experiments –
in the buffer dilutions and exposure timed chosen – protein 
ZO-1 – generally known as a major junctional plaque protein of
adherens and tight junctions (e.g. Ref. [40]; for a special review on
the problems of ‘stickiness’ of proteins of this category see also
Ref. [41]) – was dissociated from myozap.
As one of myozap’s functions we hypothesize a potential major
regulatory role in the assembly and maintenance of diverse types
of vascular adhering junctions as well as of cardiac junctions, as is
also evident from the cardiomyopathies recently reported in mor-
pholino knock-down experiments in zebrafish [18]. These findings,
combined with its demonstrated role in serum response factor
(SRF)-dependent transcription, define myozap as a novel molecule
critical for both topological stability and organisation of cell and tis-
sue architecture as well as in surface-nucleus signalling. In addi-
tion, we suspect that myozap plays a role in the regulations of the
plaque anchorage of actin filaments and hence also in cytoskeletal
organization and cell contractions as we are impressed by its tight
and complex interactions with the plaque protein plectin, present in
various kinds of junction plaques (e.g. [42, 43]). Finally, protein
myozap may also be useful as a cell type marker in developmental
biology and in pathology, in particular as a valuable immunohisto-
logical reagent in the diagnosis of certain diseases.
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